Maxim Group reiterated their buy rating on shares of DelMar Pharmaceuticals (NASDAQ:DMPI) in a report published on Friday, AnalystRatings.com reports.
Separately, Zacks Investment Research raised shares of DelMar Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, October 29th.
DMPI traded down $0.09 on Friday, reaching $0.66. 14,785 shares of the company traded hands, compared to its average volume of 726,679. The stock’s 50 day moving average price is $0.58 and its 200-day moving average price is $1.20. DelMar Pharmaceuticals has a 52-week low of $0.40 and a 52-week high of $6.80. The company has a market cap of $2.04 million, a price-to-earnings ratio of -0.21 and a beta of 1.30.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer.
See Also: What is the Bid-Ask Spread?
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.